An Act To Require Health Insurance Coverage For Biomarker Testing

LD 107 requires Maine health insurance plans, including MaineCare (Medicaid), to cover biomarker testing for diagnosis, treatment, or monitoring of diseases when supported by specific evidence. This affects patients needing biomarker tests (like genetic screenings for cancer treatment) and insurers providing health coverage in Maine. The bill mandates coverage if the test is backed by FDA approval, drug labeling, federal coverage determinations, or nationally recognized clinical guidelines. It also requires insurers to deliver testing in a way that minimizes disruptions, such as avoiding multiple biopsies. The law applies to both public and private health insurance plans in the state.